ClinicalTrials.gg
RecruitingNCT07549516ASC2ADHEREUpdated Nov 9, 2026

A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany

An observational study in Leukemia, Chronic Myeloid, sponsored by Novartis Pharmaceuticals. Recruiting at 74 sites in Germany. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 9, 202610 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
380
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis — 9 open to participants now, 13 under way, 2 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Novartis.

Planned enrollment
11th of 19
380 · median 400
Started
2026
with 3 others
Observational
19 of 92
6 open now
Primary completion
2030-09
later than 11 of 12 live
Registered
91st of 92
by date

Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 11th largest by planned enrollment of the 19 observational ones that give a count, is one of 4 that started in 2026, is one of 19 observational ones, reaches primary completion later than 11 of the 12 other live ones, and was the 91st registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

895 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 105 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

9 of the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 75 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 46 (61%) set no upper age limit and 19 (25%) stop at 75 or younger; 19 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, or all of them as a file.
02

Study summary

The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibitor (TKI).

03

Conditions studied

  • Leukemia, Chronic Myeloid

Keywords

  • Asciminib
  • CML-CP
  • Philadelphia chromosome-positive
  • Real-world evidence
  • Non-interventional study
  • Germany
  • BCR::ABL1
  • Major Molecular Response
  • Adherence
  • MARS-5
  • EORTC QLQ-C30
  • EORTC QLQ-CML24
  • WPAI-GH
  • Tyrosine kinase inhibitors
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult Ph+ CML-CP patients, either newly diagnosed or previously treated with one ATP-competitive TKI, who initiate TKI treatment as recommended by the treating physician in a hematology center in Germany.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written must be obtained before participation in the study/prior to any study-related documentation.
  2. Adult patients (≥18 years of age) with a confirmed diagnosis of Ph+ CML-CP. The presence of the Philadelphia chromosome may alternatively be confirmed by molecular detection of a BCR::ABL1 fusion gene/transcript (e.g., by reverse transcription polymerase chain reaction (RT-PCR)), in accordance with the World Health Organization (WHO) 2022 classification.
  3. Patients who are either newly diagnosed or have received treatment with exactly one prior TKI. Prior TKI treatment is only permitted for patients in the Asciminib Cohort. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be newly diagnosed and must not have received any prior TKI treatment.
  4. Patients for whom the treating physician has made a clinical decision to initiate treatment with asciminib or another TKI (imatinib, dasatinib, bosutinib, nilotinib) as part of routine care. The clinical decision for treatment must have been made prior to enrollment. Treatment must not have started more than 14 days before study inclusion, and treatment may also begin after baseline assessment.
  5. Patients willing to participate in routine follow-up visits and complete patient-reported outcome questionnaires over the course of the study.

Exclusion criteria

Exclusion criteria:

  1. Patients with to their respective chronic myeloid leukemia (CML) treatment as per the applicable Summary of Product Characteristics (SmPC) and relevant national treatment guidelines (e.g. Onkopedia CML), as well as additional disease- or treatment-related characteristics associated with distinct clinical scenarios that differ from the intended study population, including situations with specific treatment requirements or limited comparability, in which reliable interpretation of study outcomes may not be feasible, including the following asciminib specific considerations:

    • In first- or treatment: presence of BCR::ABL1 fusion transcripts lacking exon a2 (e.g. e13a3, e14a3, e1a3).
    • In second-line treatment:

      • known BCR::ABL1 mutations associated with partial or complete resistance to asciminib (e.g. M244V, F359I/V/C).
      • presence of the BCR::ABL1 T315I mutation, regardless of eligibility for treatment according to SmPC (e.g., specific indication and dosing regimens).
  2. Patients receiving or planned to receive asciminib or other TKIs outside the approved label (off-label use), including use in unapproved dosing regimens or frequency not covered by the respective SmPC.
  3. Patients currently participating in an interventional clinical trial.
  4. Patients unable or unwilling to provide written .
  5. Patients who are unable to reliably complete patient-reported outcome questionnaires due to cognitive or language limitations relevant to the study assessments.
  6. Patients for whom long-term follow-up is not feasible due to expected relocation or other logistical constraints.
  7. The restriction to a maximum of one prior ATP-competitive TKI applies exclusively to patients treated with asciminib. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be TKI-naïve and are included at the start of their first-line TKI therapy and are not eligible if they have received any prior TKI treatment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
380 participants (estimated)
Patient registry
No

Groups and cohorts

  • Asciminib Cohort

    Adult patients with Ph+ CML-CP, either newly diagnosed or previously treated with one TKI, who are treated with asciminib.

  • Imatinib Cohort

    Adult patients newly diagnosed with Ph+ CML-CP treated with imatinib who have not received any prior TKI treatment.

  • Second-generation TKI Cohort

    Adult patients newly diagnosed with Ph+ CML-CP treated with dasatinib, bosutinib, or nilotinib who have not received any prior TKI treatment.

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With Major Molecular Response (MMR) at 12 Months

    MMR is defined as a BCR::ABL1 level ≤ 0.1% according to the International Scale (IS).

    Time frame: Month 12

Secondary outcomes

  1. Percentage of Patients by Clinical Characteristic

    Characteristics include, but are not limited to, detection of Philadelphia chromosome or BCR::ABL1 transcript, prior treatment, and Eastern Cooperative Oncology Group (ECOG) performance status.

    Time frame: Baseline

  2. Percentage of Patients by Reason for TKI Treatment Decision Documented by the Treating Physician

    Time frame: Baseline

  3. Percentage of Patients With Dose Reduction by Reason for Dose Reduction

    Time frame: 3, 6, 9, 12, 15, 18, 21, and 24 months

  4. Percentage of Patients With Treatment Interruption by Reason for Interruption

    Time frame: 3, 6, 9, 12, 15, 18, 21, and 24 months

  5. Percentage of Patients Who Discontinued Treatment by Reason for Discontinuation

    Time frame: 3, 6, 9, 12, 15, 18, 21, and 24 months

  6. Time to Treatment Discontinuation

    Time frame: 3, 6, 9, 12, 15, 18, 21, and 24 months

  7. Time to Treatment Interruption

    Time frame: 3, 6, 9, 12, 15, 18, 21, and 24 months

  8. Time to Dose Reduction

    Time frame: 3, 6, 9, 12, 15, 18, 21, and 24 months

  9. Time to Treatment Discontinuation due to Adverse Events (TTDAE)

    Time frame: 3, 6, 9, 12, 15, 18, 21, and 24 months

  10. Percentage of Patients With Early Molecular Response (EMR) at 3 Months

    EMR is defined as BCR::ABL1 ≤10% IS.

    Time frame: Month 3

  11. Percentage of Patients With Molecular Response 2 (MR2)

    MR2 is defined as BCR::ABL1 ≤1% IS.

    Time frame: 3, 6, 9, 12, 15, 18, 21, and 24 months

  12. Percentage of Patients With MMR

    MMR is defined as BCR::ABL1 ≤0.1% IS.

    Time frame: 3, 6, 9, 15, 18, 21, and 24 months

  13. Percentage of Patients With Deep Molecular Response: MR4.0

    Deep Molecular Response (MR4.0): ≤0.01% BCR::ABL1 IS and Reference gene copies \>10,000 ABL1 or \>24,000 GUSB.

    Time frame: 3, 6, 9, 12, 15, 18, 21, and 24 months

  14. Percentage of Patients With Deep Molecular Response: MR4.5

    Deep Molecular Response (MR4.5): ≤0.0032% BCR::ABL1 IS and Reference gene copies \>32,000 ABL1 or \>77,000 GUSB.

    Time frame: 3, 6, 9, 12, 15, 18, 21, and 24 months

  15. Percentage of Patients With Deep Molecular Response: MR5

    Deep Molecular Response (MR5): ≤0.001% BCR::ABL1 IS and Reference gene copies \>100,000 ABL1 or \>240,000 GUSB.

    Time frame: 3, 6, 9, 12, 15, 18, 21, and 24 months

  16. Medication Adherence Report Scale (MARS-5) Score

    The MARS-5 questionnaire is a validated self-report questionnaire developed to assess patient adherence to prescribed medication, focusing on both intentional and unintentional non-adherence. It consists of 5 items, each rated on a 5-point Likert Scale from 0 (always) to 5 (never). The total score ranges from 5 to 25, with higher scores indicating better adherence to treatment.

    Time frame: 3, 6, 9, 12, 15, 18, 21, and 24 months

  17. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score

    The EORTC QLQ-C30 contains 30 questions answered by the patient. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role functioning, cognitive, emotional, and social); 3 symptom scales (fatigue, pain, and nausea and vomiting); and a global health status/Quality of Life (QOL) scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but 2 questions have 4-point scales ranging from "Not at all" to "Very much." The 2 questions concerning global health status/QOL have 7-point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, final scores are transformed such that they range from 0-100, where higher scores indicate improvement.

    Time frame: 3, 6, 9, 12, 15, 18, 21, and 24 months

  18. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for CML (EORTC QLQ-CML24) Score

    The EORTC QLQ-CML24 was designed to supplement the QLQ-C30 - the QLQ-CML24 is not a stand-alone instrument but is to be used in conjunction with the QLQ-C30. The EORTC QLQ-CML24 is composed of 4 multi-item scales and 2 single-item scales. The module consists of 24 items assessing symptom burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items are measured on 4 levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores are averaged and transformed to 0 to 100. A higher score in symptom burden, impact on worry/mood, impact on daily life, and body image problems domains indicates a worse outcome. A higher score in satisfaction with social life and satisfaction with care and information domains indicates a higher level of satisfaction.

    Time frame: 3, 6, 9, 12, 15, 18, 21, and 24 months

  19. Work Productivity and Activity Impairment - General Health (WPAI-GH) Score

    The WPAI-GH is a patient-reported 6 item questionnaire which addresses absenteeism, presenteeism, overall work productivity loss, and activity impairment for the 7 days prior to the assessment. Work productivity and activity impairment outcomes are presented as impairment percentages ranging from 0 to 100 with a higher percentage indicating greater impairment and less productivity.

    Time frame: 3, 6, 9, 12, 15, 18, 21, and 24 months

07

Study locations

74 of 74 sites recruiting
  • Novartis Investigative Site
    Baden-Baden, Baden-Wurttemberg 76532, Germany
    Recruiting
  • Novartis Investigative Site
    Heidenheim, Baden-Wurttemberg 89522, Germany
    Recruiting
  • Novartis Investigative Site
    Schwäbisch Hall, Baden-Wurttemberg 74523, Germany
    Recruiting
  • Novartis Investigative Site
    Winnenden, Baden-Wurttemberg 71364, Germany
    Recruiting
  • Novartis Investigative Site
    Aschaffenburg, Bavaria 63739, Germany
    Recruiting
  • Novartis Investigative Site
    Augsburg, Bavaria 86152, Germany
    Recruiting
  • Novartis Investigative Site
    Donauwörth, Bavaria 86609, Germany
    Recruiting
  • Novartis Investigative Site
    Herrsching am Ammersee, Bavaria 82211, Germany
    Recruiting
  • Novartis Investigative Site
    Kempten (Allgäu), Bavaria 87439, Germany
    Recruiting
  • Novartis Investigative Site
    Landsberg am Lech, Bavaria 86899, Germany
    Recruiting
  • Novartis Investigative Site
    Munich, Bavaria 81241, Germany
    Recruiting
  • Novartis Investigative Site
    Munich, Bavaria 81377, Germany
    Recruiting
  • Novartis Investigative Site
    Regensburg, Bavaria 93053, Germany
    Recruiting
  • Novartis Investigative Site
    Bremerhaven, Free Hanseatic City of Bremen 27576, Germany
    Recruiting
  • Novartis Investigative Site
    Kassel, Hesse 34125, Germany
    Recruiting
  • Novartis Investigative Site
    Offenbach, Hesse 63065, Germany
    Recruiting
  • Novartis Investigative Site
    Goslar, Lower Saxony 38642, Germany
    Recruiting
  • Novartis Investigative Site
    Rotenburg (Wümme), Lower Saxony 27356, Germany
    Recruiting
  • Novartis Investigative Site
    Twistringen, Lower Saxony 27239, Germany
    Recruiting
  • Novartis Investigative Site
    Cologne, North Rhine-Westphalia 50674, Germany
    Recruiting
  • Novartis Investigative Site
    Cologne, North Rhine-Westphalia 50677, Germany
    Recruiting
  • Novartis Investigative Site
    Cologne, North Rhine-Westphalia 51103, Germany
    Recruiting
  • Novartis Investigative Site
    Solingen, North Rhine-Westphalia 42653, Germany
    Recruiting
  • Novartis Investigative Site
    Wesel, North Rhine-Westphalia 46483, Germany
    Recruiting
  • Novartis Investigative Site
    Zittau, Saxony 02763, Germany
    Recruiting
  • Novartis Investigative Site
    Halle, Saxony-Anhalt 06110, Germany
    Recruiting
  • Novartis Investigative Site
    Merseburg, Saxony-Anhalt 06217, Germany
    Recruiting
  • Novartis Investigative Site
    Oldenburg in Holstein, Schleswig-Holstein 23758, Germany
    Recruiting
  • Novartis Investigative Site
    Altenburg, Thuringia 04600, Germany
    Recruiting
  • Novartis Investigative Site
    Saalfeld, Thuringia 07318, Germany
    Recruiting
  • Novartis Investigative Site
    Amberg, 92224, Germany
    Recruiting
  • Novartis Investigative Site
    Bad Friedrichshall, 74177, Germany
    Recruiting
  • Novartis Investigative Site
    Bad Liebenwerda, 04924, Germany
    Recruiting
  • Novartis Investigative Site
    Bad Saarow, 15526, Germany
    Recruiting
  • Novartis Investigative Site
    Berlin, 10365, Germany
    Recruiting
  • Novartis Investigative Site
    Berlin, 10437, Germany
    Recruiting
  • Novartis Investigative Site
    Berlin, 10559, Germany
    Recruiting
  • Novartis Investigative Site
    Berlin, 12487, Germany
    Recruiting
  • Novartis Investigative Site
    Berlin, 12552, Germany
    Recruiting
  • Novartis Investigative Site
    Bremerhaven, 27568, Germany
    Recruiting
  • Novartis Investigative Site
    Buchholz Nordheide, 21244, Germany
    Recruiting
  • Novartis Investigative Site
    Cottbus, 03046, Germany
    Recruiting
  • Novartis Investigative Site
    Deggendorf, 94469, Germany
    Recruiting
  • Novartis Investigative Site
    Detmold, 32756, Germany
    Recruiting
  • Novartis Investigative Site
    Dorfen, 84405, Germany
    Recruiting
  • Novartis Investigative Site
    Dortmund, 44263, Germany
    Recruiting
  • Novartis Investigative Site
    Dresden, 01127, Germany
    Recruiting
  • Novartis Investigative Site
    Dresden, 01307, Germany
    Recruiting
  • Novartis Investigative Site
    Düren, 52353, Germany
    Recruiting
  • Novartis Investigative Site
    Erfurt, 99084, Germany
    Recruiting
  • Novartis Investigative Site
    Erfurt, 99085, Germany
    Recruiting
  • Novartis Investigative Site
    Eschweiler, 52249, Germany
    Recruiting
  • Novartis Investigative Site
    Göttingen, 37073, Germany
    Recruiting
  • Novartis Investigative Site
    Hanover, 30161, Germany
    Recruiting
  • Novartis Investigative Site
    Hanover, 30625, Germany
    Recruiting
  • Novartis Investigative Site
    Hildesheim, 31135, Germany
    Recruiting
  • Novartis Investigative Site
    Kiel, 24105, Germany
    Recruiting
  • Novartis Investigative Site
    Leipzig, 04103, Germany
    Recruiting
  • Novartis Investigative Site
    Leverkusen, 51375, Germany
    Recruiting
  • Novartis Investigative Site
    Mutlangen, 73557, Germany
    Recruiting
  • Novartis Investigative Site
    Naunhof, 04683, Germany
    Recruiting
  • Novartis Investigative Site
    Neuss, 41462, Germany
    Recruiting
  • Novartis Investigative Site
    Offenburg, 77654, Germany
    Recruiting
  • Novartis Investigative Site
    Oldenburg, 26121, Germany
    Recruiting
  • Novartis Investigative Site
    Parchim, 19370, Germany
    Recruiting
  • Novartis Investigative Site
    Potsdam, 14467, Germany
    Recruiting
  • Novartis Investigative Site
    Potsdam, 14482, Germany
    Recruiting
  • Novartis Investigative Site
    Schorndorf, 73614, Germany
    Recruiting
  • Novartis Investigative Site
    Schwetzingen, 68723, Germany
    Recruiting
  • Novartis Investigative Site
    Soest, 59494, Germany
    Recruiting
  • Novartis Investigative Site
    Stade, 21680, Germany
    Recruiting
  • Novartis Investigative Site
    Torgau, 04860, Germany
    Recruiting
  • Novartis Investigative Site
    Ulm, 89081, Germany
    Recruiting
  • Novartis Investigative Site
    Wetzlar, 35578, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Sep 2030, 53 months after the start.

Of 67 observational studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's planned 53 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2026
First posted
Apr 24, 2026
StartActual
Apr 17, 2026
Primary completionEst.
Sep 30, 2030
CompletionEst.
Sep 30, 2030
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added, 1 site removed
Show 10 added (10 Germany)
  • Novartis Investigative Site · Altenburg, Germany
  • Novartis Investigative Site · Bad Saarow, Germany
  • Novartis Investigative Site · Berlin, Germany
  • Novartis Investigative Site · Deggendorf, Germany
  • Novartis Investigative Site · Erfurt, Germany
  • Novartis Investigative Site · Munich, Germany
  • Novartis Investigative Site · Cologne, Germany
  • Novartis Investigative Site · Halle, Germany
  • Novartis Investigative Site · Amberg, Germany
  • Novartis Investigative Site · Ulm, Germany
Show 1 removed
  • Novartis Investigative Site · Berlin, Germany
across 2 updates, Oct 7, 2026 – Nov 9, 2026
Show all 2 updates
  1. Nov 9, 2026
    5 sites added
    Show 5 added (5 Germany)
    • Novartis Investigative Site · Munich, Germany
    • Novartis Investigative Site · Cologne, Germany
    • Novartis Investigative Site · Halle, Germany
    • Novartis Investigative Site · Amberg, Germany
    • Novartis Investigative Site · Ulm, Germany
    + 1 other change: verification date
  2. Oct 7, 2026
    5 sites added, 1 site removed
    Show 5 added (5 Germany)
    • Novartis Investigative Site · Altenburg, Germany
    • Novartis Investigative Site · Bad Saarow, Germany
    • Novartis Investigative Site · Berlin, Germany
    • Novartis Investigative Site · Deggendorf, Germany
    • Novartis Investigative Site · Erfurt, Germany
    Show 1 removed
    • Novartis Investigative Site · Berlin, Germany
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07549516
Responsible party
Sponsor
First posted
Apr 24, 2026
Start date
Apr 17, 2026
Primary completion
Sep 30, 2030 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
Nov 9, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion